🇺🇸 FDA
Pipeline program

KYV-101

KYSA-7

Phase 2 mab active

Quick answer

KYV-101 for Multiple Sclerosis, Primary Progressive is a Phase 2 program (mab) at Kyverna Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Kyverna Therapeutics
Indication
Multiple Sclerosis, Primary Progressive
Phase
Phase 2
Modality
mab
Status
active

Clinical trials